Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies9,10
Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.
Read More
TP53 Mutations Are Associated With Unfavorable Prognosis in CLL
Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL